Pioneering a New Era In Asthma Control
Our Advanced Candidate: Dexpramipexole
Who We Are
A New Approach
How Did We Get Here?
Phase 3 Development Program
News Releases
Publications
Presentations
11.09.22
Areteia Therapeutics announces the appointment of Christopher Courts, CPA as Chief Financial Officer
Read More
10.05.22
Areteia Therapeutics announces the appointments of Dr. Eric Bradford as Chief Medical Officer, and Robin Walker as Chief Legal Officer and Corporate Secretary
09.22.22
Areteia Therapeutics named as one of the Most Promising Biotech Startups of 2022
09.07.22
Ian Read named Chairman of the Board of Areteia Therapeutics
07.12.22
Knopp Biosciences and Population Health Partners Create Areteia Therapeutics, New Clinical-Stage Asthma Company, with $350 Million in Funding
02.28.22
Knopp Biosciences Presents New Phase 2 Data at AAAAI 2022 demonstrating that oral dexpramipexole improves airflow obstruction as measured by forced expiry volume (FEV1), largely through its effect on forced vital capacity (FVC)
09.07.21
Knopp Biosciences Presents New Phase 2 Data at ERS 2021 Demonstrating that Reduction in Eosinophil Count by Dexpramipexole Significantly Correlates with Improvement in Lung Function
05.17.21
Knopp Biosciences Reports Positive Results from the Phase 2 EXHALE Trial of Oral Dexpramipexole in Moderate-to-Severe Eosinophilic Asthma at ATS 2021
01.14.21
Knopp Biosciences Announces Positive Top-Line Results from the Phase 2 EXHALE Trial of Oral Dexpramipexole in Moderate-to-Severe Eosinophilic Asthma
01.04.21
Dexpramipexole Targets Eosinophilic Inflammation
09.16.20
Knopp Biosciences Completes Enrollment in Phase 2 Trial of Oral Dexpramipexole in Eosinophilic Asthma
08.17.20
Knopp Biosciences to Present at Oppenheimer’s Private Life Sciences Company Call Series Aug. 18
07.09.19
Knopp Biosciences to Present Clinical Data for Dexpramipexole at 11th Biennial Symposium of the International Eosinophil Society
04.24.19
Knopp Biosciences Receives FDA Orphan Drug Designation for Dexpramipexole for Treatment of Hypereosinophilic Syndrome
01.16.19
Knopp Biosciences Expands Research Collaboration with Cincinnati Children’s to Characterize Effect of Dexpramipexole in Inflammatory Diseases
05.22.18
NIAID Now: Repurposed Drug Shows Promise for Treating Rare Eosinophilic Diseases
09.06.17
Knopp Biosciences and APFED Announce Partnership to Advance Awareness of Hypereosinophilic Syndromes
